The latter announced on June 17, 2011 its intention to undertake a safety review of Actos (pioglitazone). “In light of studies suggesting an increased risk of bladder cancer with the diabetes drug pioglitazone, as well as actions taken by other regulatory agencies, Health Canada is informing healthcare professionals and Canadians that it is undertaking a review of the drug's status,” the release stated.
“Should the on-going review identify new safety information, Health Canada will take appropriate action as necessary. This can include updating Canadians with new recommendations regarding pioglitazone and the potential risk,” for Actos bladder cancer.
Less than a year later that investigation was complete. On April 16, 2012 Health Canada alerted doctors and healthcare professionals as to the real, albeit rare potential for Actos and bladder cancer in association with the use of pioglitazone.
“Findings from new studies reveal that there is a potential increased risk of bladder cancer in patients treated with pioglitazone-containing products,” Health Canada stated. Most telling in the Health Canada release was reference to a fifth-year interim report of an ongoing ten-year observational cohort study in patients with diabetes.
READ MORE ACTOS SIDE EFFECTS LEGAL NEWS
Meanwhile, in the US the Gasparovic Actos lawsuit has been transferred to Cook County Court from its original jurisdiction governed by the Illinois Supreme Court, for consolidation in Actos multidistrict litigation for pre-trial discovery.
Gasparovic alleges that his use of Actos for ongoing treatment of Type 2 diabetes exposed him to Actos bladder cancer. The defendants in the Actos bladder cancer lawsuit, filed in March of this year, are Takeda Pharmaceuticals, Walgreens and Eli Lilly. Gasparovic seeks compensation for medical expenses, bodily damage, pain and suffering, anxiety and mental anguish, disability and the loss of a normal life.
The Actos lawsuit is Gasparovic v. Takeda Pharmaceuticals et al, Case No. 16-L-300.